Diovan generics approved in Japan for June launch
This article was originally published in Scrip
Executive Summary
Japan's regulatory authorities have granted the latest batch approval to a group of generics that includes versions of Novartis's blockbuster antihypertensive Diovan (valsartan), which is now set to be opened up to its first such competition around the middle of the year.